Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.
A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.
The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.
Marketers may want to dust off plans to create NP-centric materials.
Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.
Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.
The ruling stalls generics until at least September.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.
Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.
Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
Clinical trials indicate the CTEP works for specific genetic profiles.
Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.
The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.
BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.
Regeneron/Sanofi PCSK9 meets Phase-III endpoint; Anthem selects Gilead's Harvoni as primary HCV treatment; GSK and Merck about to begin human trials for Ebola vaccine.
A Phase-II study showed the schizophrenia drug performed as well as, but without the weight gain associated with, an older treatment.
AbbVie announced positive interim Phase-III results Thursday for its endometriosis drug elagolix, but one analyst says its commercial impact is likely linked to its effect on patients' bone mineral density.
The specialty biopharma firm says it's hiring new commercial managers after a buying spree.
The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
The fifth annual Xerox survey of patients and electronic health records shows patients have high expectations for the digital data.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.
Countering Express Scripts' exclusive status for AbbVie's hep.-C entry, CVS/Caremark makes Harvoni and Sovaldi preferred choices on its drug lists.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
The drugmaker launched four doses of the blood pressure medication.
Clemson University researchers found that patients are not all that honest with healthcare providers.
Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.
The committee is slated to rule on Sandoz's Zarzio Jan 7.
The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.
A CVS Health/American Council of the Blind collaboration means some visually impaired patients will soon have more engaging prescription labels.
Rebien Soerensen told a Danish paper that he expects to leave his position before 2019.
Severe flu season to test Roche's Tamiflu; Novartis gains nod for psoriasis drug; Amgen and Kite collaborate on immunotherapy.
A look at the content that grabbed most reader interest over the past year.
Pop songs about doctors get heavy rotation in BMJ; digital-health investment tally shows doubling in 2014; scientists finger bats as possible Ebola source.
The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
Nine drugs that promised meaningful advances over existing treatments earned the coveted status from FDA and were approved.
A focus on the existing Yervoy prescribing community could help Bristol-Myers Squibb drive sales of Opdivo past rival Keytruda, one analyst argues.
FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.
FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
The 8,200-store chain would expand to 11,000 locations operating in 10 countries, if shareholders approve.
The agreement between AbbVie and Express Scripts is seen as a seismic shift in the joint development of cost-effective therapies, and gives the new regimen a slight edge on Gilead's popular remedies.
The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.
The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial
Canadian firm presents FDA with its third biosimilar application.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.
Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.
Ruling voids FDA's take on reissued patents, settling a year of challenges by generic applicants
UCB generic deal falls through; agency hiring could spike in 2015; teenage prescription drug abuse is on the decline.
Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.
Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.
The new approach shows "The Talk" has a sequel.
Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.
The treatment reduces risk by half compared to widely used Zelboraf.
Court clears the way for a Nexavar generic from Natco
The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.
Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.
Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.
Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.
Philadelphia Transportation Authority sues Gilead over Sovaldi sticker shock; Digital marketing tactics raise privacy concerns; another patent cliff is on the horizon.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
As courts sort out lawsuits over two Sandoz biosimilars, the Novartis unit reports a study showing its BLA candidate has similar efficacy to Neupogen.
Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.
Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.
An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.
Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.
WSJ reported FDA advisors failed to disclose pharma financial ties; Novartis axes 200 employees in New Jersey; Takeda retires the Millennium brand.
Sun Pharma buys troubled Ranbaxy and its pipeline of promising follow-ons.
Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.
Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.
Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.
"In this era, it requires mobilizing our collective intelligence toward innovation and integration that is meaningful for large populations."
GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.
Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.
Jakafi becomes the first drug approved for treating polycythemia vera.
Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.
Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.
CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.
The bad news: heroin-related deaths inched upwards.
Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.
The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled